Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | GLP1R | P43220 | 16/20 | 0.51 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30275353 | 1.00 | KCNH2 (0.52) | KCNH2GLP1RLTA4HCYP2C8HTR2A | |
| SCHEMBL23980779 | 1.00 | KCNH2 (0.52) | KCNH2GLP1RLTA4HCYP2C8HTR2A | |
| SCHEMBL23980944 | 0.94 | GLP1R (0.54) | KCNH2GLP1RLTA4HCYP2C8HTR2A | |
| SCHEMBL23980910 | 0.94 | GLP1R (0.54) | KCNH2GLP1RLTA4HCYP2C8HTR2A | |
| SCHEMBL23981040 | 0.94 | GLP1R (0.49) | KCNH2GLP1RLTA4HCYP2C8HTR2A | |
| SCHEMBL23980951 | 0.94 | GLP1R (0.54) | KCNH2GLP1RLTA4HCYP2C8HTR2A | |
| SCHEMBL23980860 | 0.94 | GLP1R (0.55) | KCNH2GLP1RLTA4HCYP2C8HTR2A | |
| SCHEMBL23980803 | 0.94 | GLP1R (0.49) | KCNH2GLP1RLTA4HCYP2C8HTR2A | |
| SCHEMBL23981037 | 0.94 | GLP1R (0.55) | KCNH2GLP1RLTA4HCYP2C8HTR2A | |
| SCHEMBL23980912 | 0.94 | GLP1R (0.54) | KCNH2GLP1RLTA4HCYP2C8HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4143183-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KCNH2 1462/4885GLP1R 1/4885LTA4H 831/4885 |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GLP1R, NPY1R, NPY2R | KCNH2 466/4885GLP1R 1/4885LTA4H 2743/4885 |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KCNH2 1462/4885GLP1R 1/4885LTA4H 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.